The trend toward germ patents started in 1980 when a landmark U.S. Supreme Court ruling allowed the patenting of life forms. The decision in that case, which involved a bacterium that could consume oil, opened the floodgates to the patenting of genes, plants, bioengineered crops, and more.

The U.S. Centers for Disease Control and Prevention (CDC) does hold a patent on one strain of Ebola. However, it is not the type that had caused the recent outbreak, said David Sanders, professor of biological sciences at Purdue University.

Ebola-The disease was first identified in 1976 in two simultaneous outbreaks, one in Nzara, and the other in Yambuku, a village near the Ebola River from which the disease takes its name. The virus spreads by direct contact with body fluids, such as blood, of  an infected human or other animals. This may also occur through contact with an item recently contaminated with bodily fluids. Spread of the disease through the air between primates, including humans, has not been documented in either laboratory or natural conditions. Semen or breast milk of a person after recovery from EVD may carry the virus for several weeks to months.

The disease has a high risk of death, killing between 25 and 90 percent of those infected, with an average of about 50 percent. This is often due to low blood pressure from fluid loss, and typically follows six to sixteen days after symptoms appear.

Word is spreading on Internet sites that the U.S. government will profit from the Ebola crisis because a patent it holds on the virus would allow it to make money on treatments.

The government holds patents on many microbes discovered in its labs and there is “nothing nefarious” about it,” says Sanders, who has done research into how to prevent Ebola from being used as a biological weapon.

Websites including The Common Sense Show, Natural News, and White Out Press have spread the word about the U.S. patent on Ebola, along with headlines hypothesizing that government’s intention is to “raise billions from a pandemic.”

He also said that the government patents viruses and other disease-causing microbes to make sure the pathogens remain available for research purposes in the public domain. If a private company held the patents, it could potentially hold onto pathogens or charge licensing fees that would stifle research to find treatments.

“The CDC does hold some patents on life forms, but it generally does this for the common good, so a commercial company can’t come along and patent it,”

“The CDC lets researchers work with the strain without fees,”

The CDC’s patent on a strain of the Ebola virus, Ebola Bundibugyo (EboBun), was granted in 2010. The agency had applied for it a year earlier. The CDC’s genetic sequencing of the virus, which is found in Uganda, was performed in 2007, according to the patent application.

EboBun is not the strain of Ebola that spread recently. The recent outbreak, which had killed more than 3,400 people, is caused by the Zaire Ebola virus (EBOV).

The publication number CA2741523 A1 says is The “SUMMARY OF THE INVENTION” section of the patent document also clearly claims that the U.S. government is claiming “ownership” over all Ebola viruses that share as little as 70% similarity with the Ebola it “invented”:

Why would a government organization claim to have “invented” this infectious disease and then claim a monopoly over its exploitation for commercial use? It is clear that the CDC plans to claim royalties on Ebola vaccines. This certainly increases the likelihood that the vaccines will become mandatory, thus increasing the profit potential for the patent holders.

Crucell is developing an Ebola vaccine in collaboration with the Vaccine Research Center (VRC) of the NIH National Institute of Allergy and Infectious Diseases (NIAID). It has been shown to completely protect monkeys against the virus with a single dose of the vaccine.

Under the terms of the agreement with VRC, Crucell has an option for exclusive worldwide commercialization rights to the Ebola vaccine.

Crucell’s Ebola vaccine entered Phase I clinical trials in Q3 2006.  Two groups of 16 volunteers were enrolled and vaccinated. The study showed safety and immunogenicity at the doses evaluated.

In October 2008, Crucell secured a NIAID/NIH award to advance the development of Ebola and Marburg vaccines, with the ultimate aim of developing a multivalent filovirus vaccine.

The award provides funding of up to $30 million, with additional options, worth a further $40 million.

It is to understand that how much we are being lied to by the media on this topic? The work on an Ebola virus, sanctioned by the holder of the patent for the vaccine, the NIH), has been on-going since 2004 with clinical trials in 2006. This explains why the CDC and the NIH are bringing Ebola patients into the country to treat. The moment that an Ebola patient crosses the U.S. border, they become the intellectual property of the CDC, NIH and Bill and Melinda Gates! How can we not believe that this is the Hegelian Dialectic run amok in a case of problem creation, solution to the problem and reaction to the problem?

The involvement of the USAMRIID is noteworthy because the Army has long been rumored to have created Ebola and, for purposes of experimentation, implanted the artificial virus in Zaire in 1977.

When an unsuspecting public is finally told of the existence of an Ebola vaccine, the Global Fund will be in charge of the distribution of the vaccine. Interestingly, Bill Gates has donated a total of $560 million dollars to the Global Fund. The Global Fund has also positioned them to be in charge of the distribution of the “newly developed”, and not yet announced vaccines for TB and HIV.

Since the goal is the vaccination of every man, woman and child on the planet with multiple vaccines, Gates’ $560 million contribution to the Global Fund is chump change compared to the expected ROI. However, on deck is the Ebola virus.

Keywords: Ebola, EboBun, Patent, vaccine, Centers for Disease Control and Prevention, Clinical trials.